- Home
- UBFO vs ATOS Comparison
UBFO vs ATOS Comparison
Compare UBFO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBFO
- ATOS
- Stock Information
- Founded
- UBFO 1987
- ATOS 2009
- Country
- UBFO United States
- ATOS United States
- Employees
- UBFO N/A
- ATOS N/A
- Industry
- UBFO Major Banks
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- UBFO Finance
- ATOS Health Care
- Exchange
- UBFO Nasdaq
- ATOS Nasdaq
- Market Cap
- UBFO 154.8M
- ATOS 130.5M
- IPO Year
- UBFO N/A
- ATOS 2012
- Fundamental
- Price
- UBFO $8.73
- ATOS $1.01
- Analyst Decision
- UBFO
- ATOS Strong Buy
- Analyst Count
- UBFO 0
- ATOS 3
- Target Price
- UBFO N/A
- ATOS $6.25
- AVG Volume (30 Days)
- UBFO 21.9K
- ATOS 1.4M
- Earning Date
- UBFO 10-16-2025
- ATOS 11-11-2025
- Dividend Yield
- UBFO 5.33%
- ATOS N/A
- EPS Growth
- UBFO N/A
- ATOS N/A
- EPS
- UBFO 0.65
- ATOS N/A
- Revenue
- UBFO $45,922,000.00
- ATOS N/A
- Revenue This Year
- UBFO N/A
- ATOS N/A
- Revenue Next Year
- UBFO N/A
- ATOS N/A
- P/E Ratio
- UBFO $13.84
- ATOS N/A
- Revenue Growth
- UBFO N/A
- ATOS N/A
- 52 Week Low
- UBFO $7.32
- ATOS $0.55
- 52 Week High
- UBFO $10.49
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- UBFO 41.07
- ATOS 56.57
- Support Level
- UBFO $8.48
- ATOS $0.95
- Resistance Level
- UBFO $9.17
- ATOS $1.10
- Average True Range (ATR)
- UBFO 0.27
- ATOS 0.09
- MACD
- UBFO -0.05
- ATOS -0.01
- Stochastic Oscillator
- UBFO 25.71
- ATOS 35.59
About UBFO United Security Bancshares
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.